Case report: Successful treatment of non-bullous lichen planus pemphigoides with dupilumab

Front Med (Lausanne). 2022 Dec 16:9:1023458. doi: 10.3389/fmed.2022.1023458. eCollection 2022.

Abstract

Lichen planus pemphigoides (LPP) is a rare autoimmune bullous disease, characterized by the coexistence of lichen planus and subepidermal bullae. However, the minority of LPP patients present with papules rather than vesicles or blisters, which is defined as non-bullous LPP. The diagnosis of LPP relies on manifestations, histopathology, serological assay, and direct immunofluorescence of linear disposition of IgG and/or C3 at the basement membrane zone. Up to now, no standard therapeutic strategies have been proposed for the treatment of LPP. Herein, we describe an uncommon non-bullous LPP patient with widespread papules and erythema, probably induced by vaccination. During hospitalization, he had a poor response to the conventional treatment of topical and systemic corticosteroids, and his condition was finally alleviated by the addition of dupilumab. For LPP patients with a traditional medication failure, or who were not suitable for a higher dose of corticosteroids, a combination with dupilumab could be an alternative option.

Keywords: corticosteroid; dupilumab; lichen planus; lichen planus pemphigoids; non-bullous; vaccine.

Publication types

  • Case Reports